scholarly journals The Chinese Herbal Medicine Formula mKG Suppresses Pulmonary Fibrosis of Mice Induced by Bleomycin

2016 ◽  
Vol 17 (2) ◽  
pp. 238 ◽  
Author(s):  
Ying Gao ◽  
Li-Fu Yao ◽  
Yang Zhao ◽  
Li-Man Wei ◽  
Peng Guo ◽  
...  
Keyword(s):  
Herbal Medicine ◽  
Pulmonary Fibrosis ◽  
Chinese Herbal Medicine ◽  
Chinese Herbal ◽  
Chinese Herbal Medicine Formula

A pilot study on Sailuotong, a Chinese herbal medicine formula, for cognition and brain activity

2015 ◽  
Vol 2 (2) ◽  
pp. 115 ◽  
Author(s):  
Genevieve Z. Steiner ◽  
Alan Yeung ◽  
David A. Camfield ◽  
Andrew Pipingas ◽  
Andrew B. Scholey ◽  
...  
Keyword(s):  
Pilot Study ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Brain Activity ◽  
Chinese Herbal ◽  
Chinese Herbal Medicine Formula

scholarly journals Efficacy and Safety of a Chinese Herbal Medicine Formula (RCM-104) in the Management of Simple Obesity: A Randomized, Placebo-Controlled Clinical Trial

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
George Binh Lenon ◽  
Kang Xiao Li ◽  
Yung-Hsien Chang ◽  
Angela Weihong Yang ◽  
Clifford Da Costa ◽  
...  
Keyword(s):  
Placebo Group ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
Efficacy And Safety ◽  
Chinese Herbal ◽  
Simple Obesity ◽  
Obese Subjects ◽  
Chinese Herbal Medicine Formula

Objective.This study was to evaluate the efficacy and safety of a Chinese herbal medicine formula (RCM-104) for the management of simple obesity.Method.Obese subjects aged between 18 and 60 years were selected for 12-week, double-blind, randomized, placebo-controlled trial. Subjects were randomly assigned to take 4 capsules of either the RCM-104 formula (n=59) or placebo (n=58), 3 times daily for 12 weeks. Measures of BW, BMI and WC, HC, WHR and BF composition were assessed at baseline and once every four weeks during the 12 week treatment period.Results. Of the 117 subjects randomised, 92 were included in the ITT analysis. The weight, BMI and BF in RCM-104 group were reduced by 1.5 kg, 0.6 kg/m2and 0.9% and those in the placebo group were increased by 0.5 kg, 0.2 kg/m2and 0.1% respectively. There were significant differences in BW and BMI (P<0.05) between the two groups. Eleven items of the WLQOQ were significantly improved in the RCM-104 group while only 2 items were significantly improved in the placebo group. Adverse events were minor in both groups.Conclusion. RCM-104 treatment appears to be well tolerated and beneficial in reducing BW and BMI in obese subjects.

Sign in / Sign up

Export Citation Format

Share Document